Case reports on the innovative treatment option for persistent and drug refractory atrial fibrillation accompanying with tachycardia induced cardiomyopathy with LVEF of 25-30%.
Event:
ACNAP-EuroHeartCare 2022
Topic:
Clinical
Session:
Clinical cases - On demand
